The proliferation of airway smooth muscle cells (ASMC) can cause airway hyperresponsiveness (AHR). It has been reported that platelet-derived growth factor (PDGF) can stimulate the proliferation of ASMC through phosphatidylinositol 3-kinase (PI3 K) signaling pathway, which can activate Akt protein. 
I
n asthma pathogenesis, an injured epithelium releases several mediators, including endothelin-1 (ET-1), epidermal growth factor (EGF), IGF, and PDGF, to induce the proliferation of ASMC (1) (2) (3) (4) . The proliferation of ASMC is believed to be important in causing AHR, a prominent feature of airway remodeling (5) . Two major pathways-ERK 1/2 and PI3 K-are involved in the proliferation of ASMC. PI3 K pathway is involved in a very important way (6, 7) . PDGF stimulates ASMC to enter the cell cycle (8) . PDGF activates downstream effectors, including Raf-1, which activates Akt, a major downstream substrate of PI3 K pathway. Activated-Akt transmits signals that then increase the cyclin D1 level (9, 10) , repressing the transcription of CDK inhibitors, including p27
Kip1 , permitting entry into the cell cycle (11) . Cyclin D1 is an important key regulator of the G1/S transition and blocks the expression of cyclin D1, inhibiting the proliferation of ASMC (12) . The cyclin D1 promoter contains nuclear factor (NF)-B regulatory elements (13) , and NF-B also appears to be a target of activated Akt (14) . However, the role of Akt/ NF-B in the proliferation of AMSC is unclear.
PTX, a phosphodiesterase inhibitor, effectively inhibits the development of autoimmune diabetes mellitus (15) , experimental allergic encephalomyelitis (16) , and asthma in animal models (17) . Furthermore, PTX effectively reduces the proliferation of vascular smooth muscle (18) and renal mesangial cells (19) . However, whether PTX suppresses the proliferation of ASMC is unknown. PTX can reduce NF-B activity to inhibit the proliferation of cells (20) . The relationship between the Akt and the NF-B activity, and whether PTX can inhibit the proliferation of ASMC by inhibiting Akt/NF-B pathway, are unclear.
In this study, the mechanism by which PTX inhibits the proliferation of ASMC was investigated. PTX and wortmannin, a PI3 K inhibitor, inhibited the PDGF-activated phosphorylation of Akt, IB␣ degradation and nuclear translocation, and the DNA binding activity of NF-B. PTX did not affect the phosphorylation of ERK1/2 but did inhibit the phosphorylation of p70 S6 K . However, the blocking of the p70 S6 K pathway by rapamycin did not influence the expression of cyclin D1 induced by PDGF. These results indicated that PTX did not suppress expression of cyclin D1 via the Akt/p70 s6k signaling pathway. Instead, PTX inhibited the expression of cyclin D1 and cell cycle entry by suppressing the Akt/NF-B pathway.
MATERIALS
Culture of ASMC. Adult, 6 -8 wk, male Brown Norway rats were obtained from the National Laboratory Animal Center (Taipei, Taiwan). These animals were raised in normal conditions in the animal center of Changhua Christian Hospital. The study was approved by the Institutional Animal Care and Use Committee of Changhua Christian Hospital. Tracheas and bronchi were taken from Brown Norway rats. Tissues were incubated in Hanks' balanced salt solution (HBSS) with 0.1% collagenase solution (Sigma Chemical Co., St.
Louis, MO) at 37°C for 20 min. Loosened connective tissues were scraped. The tissues were cut into 0.5 mm 3 fragments, which were placed in a culture dish with complement Dulbecco's modified Eagle's medium (DMEM)/F12, 10% fetal bovine serum (FBS), 2 mM glutamine, and 100U/mL penicillin/ streptomycin (all from Invitrogen, Carlsbad, CA). They were then incubated at 37°C. Passages six to eight were used in the experiments. Cultured ASMC expressed ␣-smooth muscle actins, detected immunocytochemically.
Evaluation of cell proliferation and cell cycle progression. XTT labeling mixture reagents were used (cell proliferation Kit II, Roche Molecular Biochemicals, Indianapolis, IN). Growth-arrested cells were stimulated with recombinant rat PDGF-BB (40 ng/mL; R & D Systems, Minneapolis, MN) in the presence or absence of PTX (1-10 mM) (Sigma Chemical Co.) or PTX alone for 48 h. XTT mixture reagent was added to each well and incubated for 4 h; the absorbance at 490 nm was measured.
Growth-arrested cells were stimulated with PDGF-BB in the presence or absence of PTX for 18 h to elucidate cell cycle progression. The harvested cell pellet was added to 3 mL of cold 70% ethanol and maintained at -20°C for 30 min. The cell pellet was resuspended with 1% Triton X-100, 0.1 mg/mL RNase A and 4 g/mL propidium iodide after centrifuging. The flow cytometry (FC 500, Beckman Coulter, Inc., Fullerton, CA) was used to elucidate cell cycle progression.
Apoptosis assay and necrosis assay. Terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) assay (Mebstain apoptosis kit II, Immunotech, Marseille, France) was used to determine the percentage of cells that exhibited apoptosis. Briefly, cells were fixed with 4% paraformaldehyde, permeated with 70% ethanol, and labeled with TdT reagent before 30 L of avidin-FITC solution was added. The cells were washed twice with PBS and the pellet was resuspended in the dark. The cells were then ready for analysis using flow cytometry.
Annexin V-FITC Apoptosis Detection kit (Strong Biotech Corporation, Taiwan) was used to determine the percentage of necrotic cells. Briefly, the treatment of cells was washed with PBS and centrifuged cells at 200 g for 5 min. The cell pellet was resuspended in staining buffer for 15 min at 25°C. The cells were ready for analysis using flow cytometry. The cells were in the range of annexin V positive and PI positive, indicating necrosis cells.
RNA extraction and reverse transcriptase PCR. Total RNA was isolated using TRI reagent (Molecular Research Center, Cincinnati, OH). The cDNA was primed with oligo(dT) [12] [13] [14] [15] [16] [17] [18] and extended with reverse transcriptase (CLONTECH, Palo Alto, CA). cDNA was amplified by PCR using following primer pairs: cyclin D1, forward, 5=-CTGACACCAATCTCCTCAAC-3=; reverse, 5=-GTAGATGCACAACTT CTGG-3. GAPDH, forward, 5=-TGAAGGTCGGAGTCAACGGATTTGG-3=; reverse, 5=-CATGTGGGC-CATGAGGTCCACCAC-3=. The PCR reaction production was run on 2% agarose gel in a TAE buffer and identified after staining with ethidium bromide. The intensity of the signal was quantified (Image Station 2000R, Eastman Kodak, Rochester, NY) and normalized against GAPDH messages.
Extraction of protein and Western blot analysis. Total cellular proteins were extracted using a lysis buffer, and cytoplasm and nuclear proteins were obtained using NE-PER reagents (Pierce Biotechnology, Rockford, IL). The protein concentration was determined using Bio-Rad protein assay (Bio-Rad, Hercules, CA). Antibodies against cyclin D1, Akt, Ser473-phosphorylated Akt, phosphorylated glycogen synthase kinase 3␣/␤ (GSK3␣/␤), phosphorylated p70 S6 K (Thr389, Thr421/Ser424), p70 S6 K , phosphorylated ERK1/2, ERK1/2, IB␣ and ␤-actin were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against NF-B and p27 kip1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The secondary antibodies were purchased from Pierce Biotechnology. Cell proteins were fractionated by electrophoresis on a 10% SDS-polyacrylamide gel and were transferred onto nitrocellulose membrane, blocked, and probed with various primary antibodies. Following incubation with primary antibodies (1:1000) overnight, the membrane was washed and incubated with horseradish peroxidaseconjugated secondary antibody (1:10000) for 1 h. The blot was washed and visualized by enhanced chemiluminescence (Pierce Biotechnology). The bands were quantified and normalized against ␤-actin messages. Akt kinase assays. Akt activity was assayed using an Akt kinase assay kit (Cell Signaling Technology). Briefly, 100 g of total cellular extracts were immunoprecipitated with anti-Akt antibody and incubated with 200 M ATP and 1 g of GSK3 fusion protein for 30 min. The reactions were separated by SDS-PAGE and analyzed by Western blot with antibody against p-GSK3␣/␤ and Akt.
EMSA. An EMSA gel-shift kit was used (Pierce Biotechnology). In a binding reaction, 6 g nuclear protein was incubated with 2 L of 3= end-labeled probe and 1 g poly (dI-dC) for 20 min. Electrophoresis was performed on 4.8% polyacrylamide gel at 4°C. Samples were transferred to (ϩ) nylon membranes, blocked in blocking buffer, and then incubated with anti-biotin fragments (1:10,000) conjugated with horseradish peroxidase. Finally, bands were visualized by enhanced chemiluminescence.
Immunocytochemistry. Treated cells that grew on coverslips were washed with PBS, fixed for 20 min with 3.7% paraformaldehyde, permeabilized with 0.2% Triton/PBS for 10 min, blocked with 1% BSA in PBS overnight, and incubated with anti-NF-B (p65) antibodies (2 g/mL) for 1 h. Following washing, rhodamine-conjugated secondary antibodies (1:400) were incubated for 1.5 h. The cells on coverslips were mounted in DAPI reagent (Molecular Probes, Eugene, OR) and were analyzed using a fluorescence microscope (IX-50, Olympus Optical, Hamburg, Germany).
Statistical analysis. Statistical analyses were carried out using SPSS/ Windows (SPSS Science, Chicago, IL) software. The statistical significance was evaluated by one-way ANOVA.
RESULTS

PTX inhibited PDGF-stimulated proliferation of ASMC.
The role of PTX in the PDGF-stimulated proliferation of ASMC was investigated. After serum deprivation for 48 h, growth-arrested ASMC were treated with 10, 20, 40, 60, 80, and 160 ng/mL rrPDGF-BB. After incubation for 48 h, the rate of proliferation of cells was assayed by XTT. The net proliferation rate (⌬OD) was determined (OD 48 h -OD 0 h ) (Fig. 1A) . PDGF 40 ng/mL stimulated the greatest proliferation rate: PDGF 40 ng/mL, 0.53 Ϯ 0.07; PDGF 10 ng/mL, 0.43 Ϯ 0.01; PDGF 20 ng/mL, 0.45 Ϯ 0.05; PDGF 60 ng/mL, 0.52 Ϯ 0.05; PDGF 80 ng/mL, 0.50 Ϯ 0.02; PDGF 160 ng/mL, 0.44 Ϯ 0.02; medium only, 0.27 Ϯ 0.02; p Ͻ 0.05. Growth-arrested cells were treated with PDGF 40 ng/mL and PTX (0.1, 0.5, 1, 5, and 10 mM) for 48 h. The proliferation of (Fig. 1B) . The treatment of PTX alone affected growth of cells cultured in 10% FBS-containing medium (Fig. 1C) . These results indicated that PTX inhibited the proliferation of PDGF-stimulated ASMC.
The effects of PTX on the cell cycle progression were elucidated. Growth-arrested cells were stimulated with PDGF in the presence or absence of PTX (1 mM) for 18 h, and cell cycle profiles were obtained by flow cytometric analysis. When growth-arrested ASMC were stimulated with PDGF for 18h, only 44.74% of the cells remained in G 1 /G 0 phase. PTX significantly reduced the PDGF-stimulated G 1 -to-S progression, and 64.82% of cells had remained in G 1 /G 0 phase (Fig. 2A) .
The percentage of apoptotic cells was determined by TUNEL assays to confirm that the antiproliferative effect of PTX could not be attributed to its cytotoxicity. The results indicated that PTX (1 mM) did not induce an apoptosis response (PDGF, 9.1 Ϯ 1.9%; PTX, 3.8 0.2%) (Fig. 2B) . The percentage of necrotic cells was determined by annexin V-FITC apoptosis detection kit (Strong Biotech Corporation), and these results also indicated that PTX (1 mM) did not induce a necrosis response (PDGF, 4.3 Ϯ 0.3%; PTX, 3.87 Ϯ 0.5%) (Fig. 2C) . PTX inhibited the proliferation of cells by arresting the cell cycle, not by apoptosis or necrosis.
PTX regulates cyclin D1 and p27 kip1 expression in ASMC. Cyclin D1 is an important regulator protein in the early G 1 phase of the cell cycle (21) . In this investigation, PTX arrested PDGF-stimulated cells in G 1 /G 0 phase and influenced the level of cyclin D1.
Growth-arrested ASMC were stimulated with PDGF (40 ng/mL) in the presence or absence of PTX (1 mM). The level of cyclin D1 mRNA increased 2-24 h after PDGF stimulation (arrest group: 0.95 Ϯ 0.01; PDGF 40 ng/mL, 6 h: 2.75 Ϯ 0.18) (Fig. 3A) . The levels of cyclin D1 mRNA after stimulation of PDGF and PTX were lower than those of PDGF-treated cells at all times (PDGF 40 ng/mL, 6 h: 2.75 Ϯ 0.18; PDGF 40 ng/mL ϩ PTX 1 mM, 6 h: 0.75 Ϯ 0.04) (Fig. 3A) . PTX reduced expression of cyclin D1 protein, as did wortmannin (Fig. 3B) . Furthermore, PTX increased expression of p27 kip1 protein in PDGF-stimulated cells (Fig. 3B) . Taken together, these results indicated that PTX, like wortmannin, not only reduced the expression of cyclin D1 but also increased expression of p27 kip1 , preventing entry to the cell cycle. PTX reduces expression of cyclin D1 by PI3 K/Akt pathway. The mechanisms by which PTX suppressed cyclin D1 expression were investigated. In ASMC, PDGF can activate PI3 K pathway, increasing the expression of cyclin D1 (22) . PDGF induces the phosphorylation of Akt (ser473), ERK1/2, and p70 S6 K (23) . In this study, PTX and wortmannin reduced the phosphorylation of Akt (PDGF group, 4.4 Ϯ 0.6; PDGF ϩ PTX group, 0.4 Ϯ 0.05; PDGF ϩ wortmannin group, 0) ( Fig.  4A ) and phosphorylation of p70 S6 K (Fig. 4B ), but did not influence the phosphorylation of ERK1/2 (Fig. 4C) . However, the inhibition of p70 S6 K by rapamycin, a p70 S6 K inhibitor, did not influence the expression of cyclin D1 (Fig. 3B) . The down-regulation of Akt phosphorylation by PTX reduced the activity of Akt using Akt kinase assay in vitro (Fig. 4D) .
Akt translocates to the plasma membrane and is phosphorylated by phosphoinositide-dependent kinase, a product of PI3 (Fig. 5) . However, PTX treatment reduced the phosphorylation of Akt by a factor of three in the cell membrane fraction (PDGF group, 1.97 Ϯ 0.02; PTX group, 0.67 Ϯ 0.08). These results indicated that PTX inhibited phosphorylation of Akt in the cell membrane and PTX did not affect translocation of Akt in this experiment.
PTX inhibits the degradation of IB␣ protein and the translocation of NF-B in PDGF-stimulated ASMC. NF-B is a target protein of Akt, which is activated in PDGFstimulated proliferation of cells (14) . Whether changes in NF-B activation caused by treatment with PTX and wortmannin, inhibiting the activation of Akt, was investigated. Growth-arrested cells were stimulated with PDGF in the presence or absence of PTX for 30 min. The translocation level of NF-B was determined in cytoplasm and nuclear protein fractions. PDGF increased the translocation of NF-B into nuclei after treatment for 30 min. However, wortmannin and PTX inhibited the translocation of NF-B. PTX and wortmannin also could suppress IB␣ degradation in PDGFstimulated cells (Fig. 6A ). PTX and wortmannin had a significantly lower level of NF-B in fraction of nuclei than did the PDGF-treatment group (Fig. 6A) . The densities of NF-B in cytosol protein fractions in different groups were compared with the level of phosphorylated NF-B. PTX and wortmannin reduced a markedly level of phosphorylated-NF-B (Fig.  6B ). NF-B activity was also determined using EMSA. PDGF promoted the activity of NF-B, which was markedly inhibited by PTX and wortmannin (Fig. 6C) .
The translocation of NF-B (p65) at the single cell level was also investigated by immunofluorescence microscopy. The stimulation of ASMC with PDGF for 30 min was clearly associated with the nuclear translocation of NF-B (p65) in 90 Ϯ 10% of cells. The nuclear localization of NF-B (p65 subunit) was observed in 4 Ϯ 5% of a group of unstimulated cells. The stimulation of ASMC with PDGF plus PTX for 30 min reduced the nuclear translocation of NF-B (p65) to a level close to that of the control group (Fig. 6D) . These data indicated that PTX and wortmannin blocked PDGF-induced NF-B (P65) nuclear translocation and activity, and that PTX suppressed the PDGF-stimulated down-regulation of Akt/ NF-B to inhibit the expression of cyclin D1.
DISCUSSION
In the pathogenesis of asthma, the proliferation of ASMC is a key factor in airway remodeling. ASMC are also a source of chemokines and cytokines as they increase the recruitment and activation of inflammatory cells involved in airway inflammation (25) . Most studies on airway smooth muscle have focused on reducing the contraction in response to stimuli. Studies of the inhibition of the proliferation of ASMC are few. This study demonstrated that PTX inhibited the hyperplasia of ASMC as a potential therapeutic drug for asthma.
According previous studies, PTX significantly attenuates AHR in vivo and inhibits vascular and mesangial cell proliferation in vitro. Therefore, this study proposed that PTX inhibited the proliferation of ASMC and achieved the goal of attenuating AHR. PDGF was demonstrated to induce the proliferation of ASMC in a dose-dependent manner and PTX inhibited PDGF-stimulated cell proliferation. PTX prevented activation of Akt in cell membrane to inhibit the expression of cyclin D1 and promote p27 kip1 activation. PTX also reduced inflammatory cytokine expression and extracellular matrix accumulation (16, 26, 27) . Treatment with PTX also inhibits Th1 cytokine production. These effects may contribute to the effectiveness of PTX in reducing AHR. These results demonstrate that PTX serves as a potential drug for treating asthma, not only improving of airway remodeling but also reducing the inflammatory response.
PTX cannot change either PDGF binding to the receptor or phosphorylation of the receptor (28) . A possible mechanism of the inhibition of PDGF postreceptor signaling by treatment of PTX, particularly the PI3 K signaling pathway, has been investigated (19) . A possible mechanism by which PTX prevented Akt phosphorylation was also demonstrated. PTX inhibits phosphodiesterase activity, resulting in an increase in cAMP (18) . An increase in cAMP can inhibit proliferation (29) . cAMP inhibited the activation of Rap1 and reduced Akt phosphorylation (30) . Furthermore, PTX reduced Akt phosphorylation through cAMP-dependent protein kinase, protein kinase A (PKA), by increasing of cAMP (19) . The mechanism by which PTX reduces Akt phosphorylation in the cell membrane fraction may involve PKA, affected by an increase in cAMP.
PTX blocks proliferation of cell by inhibiting activation of NF-B by an unclear pathway (31) . The one possible mechanism is that PTX blocks the PI3 K/Akt signaling pathway and then suppresses activation of NF-B. Akt enhances the degradation of IBs and cooperates with other factors to activate NF-B (32) . Akt has also been demonstrated to be both necessary and sufficient for PDGF to induce NF-B activation (14) . This study demonstrated that PTX inhibited the proliferation of ASMC by blocking the Akt/NF-B pathway. PTX and wortmannin have been established to inhibit the activation of Akt, the degradation of IB␣, and the activity of NF-B. It also inhibited the expression of cyclin D1, reducing the proliferation of ASMC. These results might indicate that PTX attenuates the PDGF-induced Akt/NF-B pathway, inhibiting cyclin D1 expression and cell proliferation.
The activation of Akt can activate p70 S6 K
. In this study, administration of PTX reduced the phosphorylation of p70 S6 K . The blocking of the p70 S6 K pathway by rapamycin did not influence the expression of cyclin D1 induction by PDGF. Other factors might be involved in inducing the expression of cyclin D1 in the mTOR/p70 S6 K pathway. In conclusion, this study demonstrated the mechanism of PTX in asthma in vitro. These results establish that PTX inhibited the proliferation of PDGF-stimulated ASMC by inhibiting the Akt/NF-B pathway, thereby reducing the expression of cyclin D1. These data might provide useful information for treating asthma and show that PTX has potential for reducing remodeling and the inflammatory responses. 
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